Ebata Toshiya
Department of Dermatology, The Jikei University School of Medicine, Chitofuna Dermatology Clinic, Tokyo, Japan.
Curr Probl Dermatol. 2016;50:155-63. doi: 10.1159/000446084. Epub 2016 Aug 23.
Drugs may cause itching as a concomitant symptom of drug-induced skin reactions or in the form of pruritus without skin lesions. Drug-induced itch is defined as generalized itching without skin lesions, caused by a drug. Itching associated with drug-induced cholestasis is among the common dermatologic adverse events (dAEs) that induce itching. Some drugs such as opioids, antimalarials, and hydroxyethyl starch are known to induce itching without skin lesions. The clinical features and underlying proposed mechanisms of itching caused by these drugs have been specifically investigated. The recent application of targeted anticancer drugs has increased the survival rate of cancer patients. These new agents cause significant dAEs such as acneiform rashes, dry skin, hand-foot syndrome, paronychia, and itching. Itching is a common side effect of epidermal growth factor receptor inhibitors. Though not life-threatening, these dAEs have a negative impact on a patient's quality of life, leading to dose reduction and possibly less effective cancer therapy. It is important to provide an effective supportive antipruritic treatment without interruption of the administration of these drugs. This chapter concludes by describing basic measures to be taken for diagnosis and treatment of drug-induced itch. The principle of treatment is discontinuation of suspected causative drugs in general except for anticancer medications. In case itching lasts long after drug withdrawal or the causative drug cannot be stopped, vigorous symptomatic antipruritic treatment and specific therapies for different types of drug-induced itch should be undertaken.
药物可能会导致瘙痒,作为药物性皮肤反应的伴随症状,或表现为无皮肤损害的瘙痒症。药物性瘙痒定义为由药物引起的无皮肤损害的全身性瘙痒。与药物性胆汁淤积相关的瘙痒是引起瘙痒的常见皮肤不良事件(dAEs)之一。已知一些药物,如阿片类药物、抗疟药和羟乙基淀粉,可引起无皮肤损害的瘙痒。这些药物引起瘙痒的临床特征和潜在机制已得到专门研究。靶向抗癌药物的近期应用提高了癌症患者的生存率。这些新药会引起显著的皮肤不良事件,如痤疮样皮疹、皮肤干燥、手足综合征、甲沟炎和瘙痒。瘙痒是表皮生长因子受体抑制剂的常见副作用。尽管这些皮肤不良事件不会危及生命,但会对患者的生活质量产生负面影响,导致剂量减少,可能使癌症治疗效果降低。在不中断这些药物给药的情况下提供有效的支持性止痒治疗很重要。本章最后描述了药物性瘙痒诊断和治疗应采取的基本措施。一般治疗原则是停用可疑的致病药物,但抗癌药物除外。如果停药后瘙痒持续很长时间或无法停用致病药物,则应进行积极的对症止痒治疗以及针对不同类型药物性瘙痒的特异性治疗。